ccc_R08

• UNSPSC Description:

  ccc_R08 is a non-cytotoxic and orally active cccDNA inhibitor that reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study of HBV virus (hepatitis B virus) infection[1][2].

• Target Antigen:

  DNA/RNA Synthesis; HBV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/ccc-r08.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1C=C(C2=CC=C(OCCOC3CC(C(O)=O)C3)C=C2)OC4=C1C=CC=C4Cl

• Molecular Weight:

  414.84

• References & Citations:

  [1]Wang L, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. |[2]Ligat G, et al. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatol Rep. 2020 Sep;19(3):235-244.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2919019-72-8